BNET Industries
HI-Tech Pharmacal Co. Inc. (HITK) is in the Pharma Industry
- Revenue
- Apr 30 2007
- $58.8M
- Profit
- Apr 30 2007
- ($2.0M)
- Market Cap
- Jul 02 2008
- $115.7M
Latest News and Analysis
Hi-Tech Pharmacal to Present at the UBS Global Specialty and Generic Pharmaceuticals Conference
AMITYVILLE, N.Y. -- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that it is scheduled to make an investor presentation at the UBS Global Specialty and Generic Pharmaceuticals Conference. David Seltzer, President and Chief Executive Officer, will deliver the Company's presentation on Wednesday, May 28, 2008, at 3:00 p.m. London...
Hi-Tech Pharmacal Launches Authorized Generic of Warner Chilcott's Dovonex® Scalp Solution
AMITYVILLE, N.Y. -- Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) announced today that it entered into a distribution and supply agreement with a subsidiary of Warner Chilcott Limited (NASDAQ:WCRX) to market the authorized generic version of Warner Chilcott's Dovonex[R] Scalp Solution (calcipotriene solution 0.005%). It is indicated for the topical treatment of...
Hi-Tech Pharmacal Receives Tentative Approval for Dorzolamide Hydrochloride with Timolol Maleate Ophthalmic Solution
AMITYVILLE, N.Y. -- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that the US Food and Drug Administration FDA has granted tentative approval to the Company's Abbreviated New Drug Application ANDA for dorzolamide hydrochloride with timolol maleate ophthalmic solution. Hi-Tech's dorzolamide hydrochloride with timolol maleate ophthalmic solution is the generic...
Hi-Tech Pharmacal Co. Inc. Review in Progress.
M2 PRESSWIRE-18 March 2008-The Maybach Journal: Hi-Tech Pharmacal Co. Inc. Review in ProgressC1994-2008 M2 COMMUNICATIONS LTD RDATE:18032008 MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Investors wanting to know the truth about...
Hi-Tech Pharmacal Receives Final Approval for Ofloxacin Otic Solution
AMITYVILLE, N.Y. -- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that the US Food and Drug Administration FDA has granted final approval to the Company's Abbreviated New Drug Application ANDA for Ofloxacin otic solution, 0.3%. Hi-Tech's Ofloxacin otic solution is the generic equivalent of Daiichi's Floxin([R]) otic solution, 0.3%...
Hi-Tech Pharmacal Reports Financial Results for the Third Fiscal Quarter Ended January 31, 2008
AMITYVILLE, N.Y. -- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the third quarter ended January 31, 2008. For the three months ended January 31, 2008, the Company reported net sales of $15.1 million, a decrease of 16% from $18.0 million for the same period last...
Hi-Tech Pharmacal to Release Third Quarter Earnings and Hold Conference Call on March 10, 2008
AMITYVILLE, N.Y. -- Second graph, first sentence should read: To access the conference call, dial toll free 888-713-4214, or 617-213-4866 for international callers, five minutes before the conference (sted To access the conference call, dial toll free 866-713-4214, or 617-213-4866 for international callers, five minutes before the conference). ...
Hi-Tech Pharmacal Receives Approval for Hydrocodone Bitartrate and Homatropine Methylbromide Syrup
AMITYVILLE, N.Y. -- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that the US Food and Drug Administration FDA has granted an approval to the Company's Abbreviated New Drug Application ANDA for Hydrocodone Bitartrate and Homatropine Methylbromide Syrup, the generic equivalent of Endo Pharmaceuticals' Hycodan[R]. Hydrocodone Bitartrate and Homatropine Methylbromide...
Hi-Tech Pharmacal Receives Final Approval for Fluticasone Propionate Nasal Spray, 50mcg
AMITYVILLE, N.Y. -- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that the US Food and Drug Administration FDA has granted final approval to the Company's Abbreviated New Drug Application ANDA for fluticasone propionate nasal spray, 50mcg. Hi-Tech's fluticasone propionate nasal spray is the AB-rated generic equivalent of GlaxoSmithKline's Flonase[R],...
Hi-Tech Pharmacal Acquires Midlothian Laboratories
AMITYVILLE, N.Y. -- Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) announced today the signing of a definitive agreement under which Hi-Tech acquired the assets of Midlothian Laboratories, LLC for $5.0 million in an all-cash transaction. Additionally, Hi-Tech will pay approximately $0.9 million for inventory and potentially up to $1.0 million in performance...
Hi-Tech Pharmacal Reports Financial Results for the Second Fiscal Quarter Ended October 31, 2007
AMITYVILLE, N.Y. -- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the quarter ended October 31, 2007. For the three months ended October 31, 2007, the Company reported net sales of $15.9 million, a decrease of 2% from $16.3 million for the same period last year....
Hi-Tech Pharmacal to Release Second Quarter Earnings and Hold Conference Call on December 7, 2007
AMITYVILLE, N.Y. -- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced that the Company will release results for its second quarter of Fiscal Year 2008 ended October 31, 2007, prior to the market opening on Friday December 7, 2007 and will hold a conference call to discuss its financial results at...
Hi-Tech Pharmacal to Present at the CIBC 18th Annual Healthcare Conference
AMITYVILLE, N.Y. -- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that it is scheduled to make an investor presentation at the CIBC 18th Annual Healthcare Conference. David Seltzer, President and Chief Executive Officer, will deliver the Company's presentation on Monday, November 5, 2007, at 1:55 p.m. Eastern Time. The...
Hi-Tech Pharmacal to Present at the UBS Global Life Sciences Conference
AMITYVILLE, N.Y. -- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that it is scheduled to make an investor presentation at the UBS Global Life Sciences Conference. David Seltzer, President and Chief Executive Officer, will deliver the Company's presentation on Tuesday, September 25, 2007, at 10:00 a.m. Eastern Time. The...
Hi-Tech Pharmacal Receives Approval for Ciclopirox Topical Solution
AMITYVILLE, N.Y. -- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that the US Food and Drug Administration FDA has granted final approval to the Company's Abbreviated New Drug Application ANDA for Ciclopirox topical solution, 8%. Hi-Tech's Ciclopirox topical solution is the generic equivalent of Dermik Laboratories' nail fungus treatment...
Hi-Tech Pharmacal Reports First Fiscal Quarter Results
AMITYVILLE, N.Y. -- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the Company's fiscal first quarter ended July 31, 2007. Quarterly Results Net sales for the three months ended July 31, 2007 were $10,098,000, a decrease of $1,220,000 compared to the net sales of...
Hi-Tech Pharmacal to Release First Quarter Earnings and Hold Conference Call on September 7, 2007
AMITYVILLE, N.Y. -- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced that the Company will release results for its first quarter of Fiscal Year 2008 ended July 31, 2007, prior to the market opening on Friday September 7, 2007 and will hold a conference call to discuss its financial results at...
Hi Tech Pharmacal Co. Inc. Swinging to a 4Q Loss.
M2 PRESSWIRE-12 July 2007-STOCKREPORT: Hi Tech Pharmacal Co. Inc. Swinging to a 4Q LossC1994-2007 M2 COMMUNICATIONS LTD RDATE:12072007 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world can communicate. Do you...
Trading Alert for Hi Tech Pharmacal Co. Inc.
M2 PRESSWIRE-11 July 2007-Biotech News: Trading Alert for Hi Tech Pharmacal Co. Inc.C1994-2007 M2 COMMUNICATIONS LTD RDATE:11072007 Hi-Tech Pharmacal combines imitation with innovation, making and distributing more than 100 liquid and semi-solid prescription, over-the-counter, and nutritional products. The company produces generic...
Hi-Tech Pharmacal Reports Financial Results for the Fourth Fiscal Quarter and Year Ended April 30, 2007
AMITYVILLE, N.Y. -- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the quarter and fiscal year ended April 30, 2007. Fourth Quarter Results For the three months ended April 30, 2007, the Company reported net sales of $13.3 million, a decrease of 27% from...
- Next »
- page 1 of 12
- « Previous
- Incorporated: 1983
- CEO: Mr. David S. Seltzer
- Employees: 247
Key Competitors
HI-Tech Pharmacal Co. Inc. Company Info
Board of Directors
Mr. David S. Seltzer
Chairman
Mr. Reuben Seltzer
Mr. Martin M. Goldwyn
Dr. Yashar Hirshaut M.D.
Mr. Robert M. Holster
Mr. Anthony J. Puglisi
Mr. Bruce W. Simpson
Contact Information
369 Bayview Avenue
Amityville, NY
631 789-8228
